BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15555209)

  • 21. Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor.
    Yokoi A; McCrudden KW; Huang J; Kim ES; Soffer SZ; Frischer JS; Serur A; New T; Yuan J; Mansukhani M; O'Toole K; Yamashiro DJ; Kandel JJ
    Oncol Rep; 2003; 10(5):1271-4. PubMed ID: 12883692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic index expression of cyclin-D1, cerbB-2 and VEGF: metastases vs corresponding primary cancers and metastatic vs non-metastatic adenocarcinomas.
    Parra ER; Park JY; Saito DM; Takagaki TY; Rodrigues OR; Capelozzi VL
    Histol Histopathol; 2008 Aug; 23(8):987-93. PubMed ID: 18498074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery.
    Galizia G; Ferraraccio F; Lieto E; Orditura M; Castellano P; Imperatore V; Romano C; Vollaro M; Agostini B; Pignatelli C; De Vita F
    Dis Colon Rectum; 2004 Nov; 47(11):1904-14. PubMed ID: 15622584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
    Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
    Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
    Haque AK; Syed S; Lele SM; Freeman DH; Adegboyega PA
    Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):103-9. PubMed ID: 12051626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma.
    Szajewski M; Kruszewski WJ; Lakomy J; Ciesielski M; Kawecki K; Jankun J; Buczek T; Szefel J
    Oncol Rep; 2014 Jan; 31(1):125-30. PubMed ID: 24173916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
    Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
    Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
    Gaffney DK; Haslam D; Tsodikov A; Hammond E; Seaman J; Holden J; Lee RJ; Zempolich K; Dodson M
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):922-8. PubMed ID: 12829126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival.
    Lei S; Appert HE; Nakata B; Domenico DR; Kim K; Howard JM
    Int J Pancreatol; 1995 Feb; 17(1):15-21. PubMed ID: 8568330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
    Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
    Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.
    Farzand S; Siddique T; Saba K; Bukhari MH
    World J Gastroenterol; 2014 May; 20(19):5889-96. PubMed ID: 24914350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study.
    Verri E; Guglielmini P; Puntoni M; Perdelli L; Papadia A; Lorenzi P; Rubagotti A; Ragni N; Boccardo F
    Oncology; 2005; 68(2-3):154-61. PubMed ID: 16020953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma.
    Zahir ST; Tafti HF; Rahmani K
    Asian Pac J Cancer Prev; 2014; 15(15):6425-8. PubMed ID: 25124637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
    Potti A; Moazzam N; Langness E; Sholes K; Tendulkar K; Koch M; Kargas S
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):80-6. PubMed ID: 14634801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.
    Liang JF; Wang HK; Xiao H; Li N; Cheng CX; Zhao YZ; Ma YB; Gao JZ; Bai RB; Zheng HX
    J Exp Clin Cancer Res; 2010 Jun; 29(1):71. PubMed ID: 20565704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.